STATINS AND PRO-INFLAMMATORY CYTOKINES IN IHD AFTER CORONARY STENTING

Солеева Ситора Шахобовна

Journal of cardiorespiratory research/Kardiorespirator tadqiqotlar jurnali · 2022-yil

Annotatsiya

Today, the problem of ischemic heart disease remains the main cause of cardiovascular complications and death. With the development and implementation of new technologies for percutaneous coronary intervention (PCI), the problem of choosing between radical and conservative management of patients is becoming more and more urgent. The role of PCI in the treatment of patients with coronary artery disease has two main objectives: improving the prognosis and reducing the severity of angina pectoris and improving the quality of life. The main cause of coronary artery disease is atherosclerosis, which is influenced by inflammatory mediators, various proteins, proteins, enzymes of  the  lipid transport  system  and  markers of myocardial damage. The primary trigger of the atherosclerotic process is the increased content of cytokines in the peripheral blood against the background of fluctuations in the initial cholesterol level. Atherogenic cholesterol is the central initial factor of cytokine overproduction in atherogenesis. Endothelial dysfunction is an early, preclinical phase of the development of coronary atherosclerosis and can be considered as the "gold standard" in assessing the functional state of the endothelium. A positive effect on endothelial function has been demonstrated in HMG-CoA reductase inhibitors, in particular rosuvastatin, which thus reduces the risk of PCI-related adverse events.  Statins, in addition to their main hypolipidemic effect, have pleiotropic properties - anti-inflammatory, antithrombotic, and immunomodulatory effects. In addition, initial retrospective clinical trials have shown that statins have the potential to improve clinical outcomes in COVID-19 patients. If these benefits are proven in randomized trials, statins could also be a useful therapy for COVID-19. Despite the conduct of dozens of multicenter studies that have  proven  the  hypolipidemic  properties  of  statins,  in  particular,  rosuvastatin,  their  questions regarding  the  correction  of  EF,  lipid  FRO  processes,  and  the  inflammatory  reaction  at  the  site  of  atherogenesis  remain insufficiently studied, and this, in turn, has an important prognostic value.

Maqola ma’lumotlari
MualliflarСолеева Ситора Шахобовна
JurnalJournal of cardiorespiratory research/Kardiorespirator tadqiqotlar jurnali
Nashr sanasi2022-06-29
Jild3
Son2
TilRus

Kalit so‘zlar

Чрескожное коронарное вмешательство, ишемическая болезнь сердца, статины, провоспалительные цитокины, фактор некроза опухоли, атеросклероз, стентирование коронарных артерий, Covid-19, SARSCoV-2, Percutaneous coronary intervention, Ischemic heart disease, Statins, Pro-inflammatory cytokines, Tumor necrosis factor, Atherosclerosis, Stenting of coronary arteries, Covid-19, SARSCoV-2, Teri osti koronar aralashuv, yurak ishemik kasalligi, statinlar, yallig'lanishga qarshi sitokinlar, o'sma nekrozi omili, ateroskleroz, koronar arteriyalarni stentlash, Covid-19, SARSCoV-2

Ilmiy soha

Journal of cardiorespiratory research/Kardiorespirator tadqiqotlar jurnali jurnalidan boshqa maqolalar

Journal of cardiorespiratory research/Kardiorespirator tadqiqotlar jurnali — barcha maqolalar